Bionexus Gene Lab Stock Buy Hold or Sell Recommendation
| BGLC Stock | USD 0.58 0.04 6.45% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding BioNexus Gene Lab is 'Strong Sell'. Macroaxis provides BioNexus Gene buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BGLC positions. The advice algorithm takes into account all of BioNexus Gene's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting BioNexus Gene's buy or sell advice are summarized below:
Real Value 0.56 | Hype Value 0.39 | Market Value 0.58 | Naive Value 0.54 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell BioNexus Gene Lab given historical horizon and risk tolerance towards BioNexus Gene. When Macroaxis issues a 'buy' or 'sell' recommendation for BioNexus Gene Lab, the advice is generated through an automated system that utilizes algorithms and statistical models.
BioNexus |
Execute BioNexus Gene Buy or Sell Advice
The BioNexus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on BioNexus Gene Lab. Macroaxis does not own or have any residual interests in BioNexus Gene Lab or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute BioNexus Gene's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
BioNexus Gene Trading Alerts and Improvement Suggestions
| BioNexus Gene Lab is way too risky over 90 days horizon | |
| BioNexus Gene Lab has some characteristics of a very speculative penny stock | |
| BioNexus Gene Lab appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 9.77 M. Net Loss for the year was (2.63 M) with profit before overhead, payroll, taxes, and interest of 2.19 M. | |
| BioNexus Gene Lab currently holds about 1.34 M in cash with (1.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 64.0% of the company shares are held by company insiders | |
| Latest headline from investorplace.com: MARA Stock Alert Get Ready for the Bitcoin Halving |
BioNexus Gene Returns Distribution Density
The distribution of BioNexus Gene's historical returns is an attempt to chart the uncertainty of BioNexus Gene's future price movements. The chart of the probability distribution of BioNexus Gene daily returns describes the distribution of returns around its average expected value. We use BioNexus Gene Lab price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of BioNexus Gene returns is essential to provide solid investment advice for BioNexus Gene.
| Mean Return | 3.06 | Value At Risk | -19.42 | Potential Upside | 26.32 | Standard Deviation | 36.76 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of BioNexus Gene historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
BioNexus Gene Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Borrowings | 1.4K | (17.8K) | (4.9K) | (1.9K) | (1.7K) | (1.8K) | |
| Capital Expenditures | 12.8K | 421.6K | 3.2K | 54.2K | 149.4K | 136.9K | |
| Change To Inventory | 7.7K | 147.0K | (345.7K) | 544.1K | (160.4K) | (152.4K) | |
| Change In Cash | (401.2K) | 1.9M | (663.8K) | (5.1K) | 3.8M | 4.0M | |
| Depreciation | 53.3K | 101.6K | 108.2K | 105.4K | 108.4K | 83.7K | |
| Net Income | (246.5K) | 1.1M | 751.6K | (356.0K) | (2.6M) | (2.5M) | |
| End Period Cash Flow | 859.1K | 2.8M | 2.1M | 2.1M | 5.9M | 6.2M | |
| Free Cash Flow | (230.1K) | 131.1K | 6.0K | 489.9K | (1.5M) | (1.4M) |
BioNexus Gene Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to BioNexus Gene or Chemicals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that BioNexus Gene's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a BioNexus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 4.63 | |
β | Beta against NYSE Composite | -18.44 | |
σ | Overall volatility | 37.62 | |
Ir | Information ratio | 0.08 |
BioNexus Gene Volatility Alert
BioNexus Gene Lab is showing large volatility of returns over the selected time horizon. BioNexus Gene Lab is a potential penny stock. Although BioNexus Gene may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in BioNexus Gene Lab. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on BioNexus instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.BioNexus Gene Fundamentals Vs Peers
Comparing BioNexus Gene's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze BioNexus Gene's direct or indirect competition across all of the common fundamentals between BioNexus Gene and the related equities. This way, we can detect undervalued stocks with similar characteristics as BioNexus Gene or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of BioNexus Gene's fundamental indicators could also be used in its relative valuation, which is a method of valuing BioNexus Gene by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare BioNexus Gene to competition |
| Fundamentals | BioNexus Gene | Peer Average |
| Return On Equity | -0.32 | -0.31 |
| Return On Asset | -0.13 | -0.14 |
| Profit Margin | (0.27) % | (1.27) % |
| Operating Margin | 0.07 % | (5.51) % |
| Current Valuation | 4.5 M | 16.62 B |
| Shares Outstanding | 17.67 M | 571.82 M |
| Shares Owned By Insiders | 64.37 % | 10.09 % |
| Shares Owned By Institutions | 0.50 % | 39.21 % |
| Number Of Shares Shorted | 43.36 K | 4.71 M |
| Price To Earning | 350.00 X | 28.72 X |
| Price To Book | 1.22 X | 9.51 X |
| Price To Sales | 1.14 X | 11.42 X |
| Revenue | 9.77 M | 9.43 B |
| Gross Profit | 2.19 M | 27.38 B |
| EBITDA | (2.49 M) | 3.9 B |
| Net Income | (2.63 M) | 570.98 M |
| Cash And Equivalents | 1.34 M | 2.7 B |
| Cash Per Share | 0.01 X | 5.01 X |
| Total Debt | 133.4 K | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 3.84 X | 2.16 X |
| Book Value Per Share | 0.55 X | 1.93 K |
| Cash Flow From Operations | (1.3 M) | 971.22 M |
| Short Ratio | 0.15 X | 4.00 X |
| Earnings Per Share | (0.18) X | 3.12 X |
| Beta | 1.95 | -0.15 |
| Market Capitalization | 10.28 M | 19.03 B |
| Total Asset | 11.4 M | 29.47 B |
| Retained Earnings | (1.84 M) | 9.33 B |
| Working Capital | 6.42 M | 1.48 B |
| Net Asset | 11.4 M |
Note: BioNexus Gene exotic insider transaction detected [view details]
BioNexus Gene Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as BioNexus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About BioNexus Gene Buy or Sell Advice
When is the right time to buy or sell BioNexus Gene Lab? Buying financial instruments such as BioNexus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2022 | 2023 | 2024 (projected) | Common Stock | 10.9M | 17.2M | 9.4M | Total Current Assets | 6.0M | 8.0M | 4.5M |
Use Investing Ideas to Build Portfolios
In addition to having BioNexus Gene in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Obamacare Repeal Thematic Idea Now
Obamacare Repeal
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Repeal Theme or any other thematic opportunities.
| View All Next | Launch |
Check out BioNexus Gene Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for BioNexus Stock analysis
When running BioNexus Gene's price analysis, check to measure BioNexus Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNexus Gene is operating at the current time. Most of BioNexus Gene's value examination focuses on studying past and present price action to predict the probability of BioNexus Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNexus Gene's price. Additionally, you may evaluate how the addition of BioNexus Gene to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is BioNexus Gene's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (0.18) | Revenue Per Share 0.615 | Quarterly Revenue Growth (0.20) | Return On Assets (0.13) |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.